Newest Verilife Dispensary To Celebrate Grand Opening November 6th
Launches Pennsylvania Expansion
PHILADELPHIA–(BUSINESS WIRE)–PharmaCann Inc., one of the nation’s largest privately held vertically integrated cannabis companies, announced today the opening of its newest Verilife location in Plymouth Meeting, Pennsylvania. This will mark the company’s fifth Pennsylvania dispensary.
“As we expand in Pennsylvania, we are pleased to broaden our service to new patients and communities starting with the addition of our newest Verilife location in Plymouth Meeting,” said Bill McMenamy, President of Verilife. “Our team is committed to ensuring all patients across Pennsylvania communities have access to our diverse menu of products that allows them to improve their lives through cannabis.”
To serve additional communities across Pennsylvania, PharmaCann has plans, pending final regulatory approval, to open new Verilife dispensary locations in Lancaster, Quakertown, and Pottstown. This expansion will add to the existing Verilife locations in Chester, Manayunk, Williamsport and Shamokin.
Verilife Plymouth Meeting is located at 601 W Germantown Pike and will be open seven days a week for Pennsylvania medical marijuana patients and caregivers. Visit www.verilife.com/pa for details.
About Verilife
PharmaCann Inc. operates its dispensaries under the name Verilife. Verilife is committed to helping people feel better and live better by dispelling outdated perceptions associated with cannabis and encouraging a new appreciation of its many benefits. For more information, please visit www.verilife.com.
About PharmaCann
PharmaCann Inc. one of the nation’s largest privately held, vertically integrated cannabis companies, providing safe, reliable, and high-quality cannabis products to people in both the medical and adult-use markets. The PharmaCann geographic footprint includes dispensaries and cultivation and processing operations in six states. For more information about PharmaCann, please visit www.pharmacann.com.
Contacts
Beth Coronelli
312-667-6260 ext. 322019
[email protected]
_(1).jpg "Marinus Pharmaceuticals Announces New Clinical and Research Data to be Presented at American Epilepsy Society Meeting"){kind=logo}
